On April 10th, a federal judge in Virginia rejected PMI's request for a permanent injunction to prevent Reynolds from selling Vuse e-cigarettes, as PMI alleges Reynolds has infringed upon its patent.
The judge stated in their ruling that prohibiting electronic smoking devices would harm public health.
Renault must pay PMI patent fees.
Judge Leonie Brinkema in the Eastern District of Virginia has ordered Renault to pay patent royalties of 1.8% of net sales for infringing on patents used in Vuse Altopod, and 2.2% of net sales for infringing on patents used in Vuse Solo G2pod.
The patent fee will be enforced throughout the remaining term of the patent and paid on a quarterly basis.
PMI has stated that if the permanent ban is not approved, they will request a patent fee of 33.5% for Altopod and 3.75% for Solo G2pod.
These patent fees are additional costs awarded by a jury ruling in 2022, totaling $10.91 million for Alto's infringement and $3.16 million for Solo G2's infringement.
According to Nielsen's latest convenience store sales report for tobacco products, Vuse is the best-selling brand with a market share of 42.2%, followed by Juul with 26.1%.
Reference materials/sources:
A judge has ruled that Reynolds is permitted to continue selling their product, Vuse.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
